Ulobetasol
- Generic Name
- Ulobetasol
- Brand Names
- Bryhali, Duobrii, Lexette, Ultravate, Ultravate X Ointment
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClF2O4
- CAS Number
- 98651-66-2
- Unique Ingredient Identifier
- 9P6159HM7T
- Background
Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.
Ulobetasol was granted FDA approval on 17 December 1990.
- Indication
Ulobetasol cream and ointment are indicated in the treatment of inflammatory and pruritic corticosteroid responsive dermatoses. Ulobetasol lotion is indicated in the treatment of plaque psoriasis.
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis), Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis
- Associated Therapies
- -
Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
Phase 3
Active, not recruiting
- Conditions
- Acne Keloidalis NuchaeAKN
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 30
- Registration Number
- NCT05608499
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2010-09-02
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 140
- Registration Number
- NCT00715975
- Locations
- 🇧🇷
Lal Clinica, Valinhos, Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath